Synthetic peptide corresponding to Human MYLK3 aa 40-69 (N terminal) conjugated to Keyhole Limpet Haemocyanin (KLH).
A375 cell lysate. Human breast carcinoma tissue.
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Preservative: 0.09% Sodium Azide
Concentration information loading...
Protein G purified
ab71826 is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Abpromise guarantee covers the use of
in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/50 - 1/100.
1/100 - 1/500. Detects a band of approximately 86 kDa (predicted molecular weight: 86 kDa).
Anti-MYLK3 antibody 图像
Western blot - Anti-MYLK3 antibody (ab71826)
Anti-MYLK3 antibody (ab71826) + Mouse heart lysate at 35 µg
Predicted band size : 86 kDa
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MYLK3 antibody (ab71826)
Formalin-fixed and paraffin-embedded human breast carcinoma tissue reacted with MYLK3 antibody (N-term) (ab71826), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining.
Western blot - Myosin light chain kinase antibody - N-terminal (ab71826)
Anti-MYLK3 antibody (ab71826) at 1/100 dilution + A375 cell lysate at 12.5 µg
Secondary HRP-anti-rabbit Predicted band size : 86 kDa Observed band size : 86 kDa Additional bands at : 30 kDa,50 kDa,55 kDa. We are unsure as to the identity of these extra bands.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Myosin light chain kinase antibody - N-terminal (ab71826)
ab71826 at 1/50 dilution, staining Myosin light chain kinase in human breast carcinoma by Immunohistochemistry using formalin-fixed, paraffin-embedded tissue, followed by peroxidase-conjugated secondary antibody and DAB staining.
Anti-MYLK3 antibody (ab71826)参考文献
This product has been referenced in:
et al. Nodes-and-connections RNAi knockdown screening: identification of a signaling molecule network involved in fulvestrant action and breast cancer prognosis. Oncogenesis 4:e172 (2015).
Read more (PubMed: 26479444) »
See 1 Publication
for this product
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"